bluebird bio Inc
NASDAQ:BLUE
NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

  • LAST PRICE
    0.4640
  • TODAY'S CHANGE (%)
    -0.0248 (-5.0736%)
  • Bid / Lots
    0.4706/ 20
  • Ask / Lots
    0.4730/ 1
  • Open / Previous Close
    0.4888 / 0.4888
  • Day Range
    0.4611
    0.4950
  • 52 Week Range
    0.4529
    5.5300
  • Volume
    4,181,817

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Oct 4, 2024

      Show headlines and story abstract

    • 4:05PM ET on Friday Oct 04, 2024 by Dow Jones
      Companies Mentioned: BLUE

      bluebird bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
      SOMERVILLE, Mass.--(BUSINESS WIRE)--October 04, 2024--
      bluebird bio, Inc. (Nasdaq: BLUE) today announced that the Compensation Committee of the Company's Board of Directors approved the grant of inducement awards of 242,500 restricted stock units (RSUs). This includes the previously disclosed 100,000 RSUs granted to the Company's CFO, James Sterling, with a grant date of September 30, 2024 and 142,500 RSUs granted to 19 other employees, with a grant date of October 1, 2024 (collectively, the "Inducement Grants"). The Inducement Grants are subject to the terms and conditions of award agreements covering the grants and the Company's 2021 Inducement Plan.

Peers Headlines